Drug Trial Radar · NCT06710847
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
14
Actual
Start
Dec 13, 2024
Primary completion
Jun 22, 2026
Study completion Jun 22, 2026
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- IDEAYA Biosciences
- First posted
- Nov 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK4418959 alone or in combination with a PD-1 inhibitor agent can decrease tumor size, is safe, well-tolerated, and how amounts of the study drug decrease in the body over time.
Conditions
- Neoplasms, Colorectal
- Solid Tumor
- Colon Cancer
- Rectal Cancer
- Endometrial Cancer
Interventions
GSK4418959Drug
GSK4418959 will be administered.
PD-1 inhibitorBiological
PD-1 inhibitor will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of participants with dose limiting toxicities (DLTs) during DLT observation periodTime frame: Up to 21 days
- Part 3: Number of participants with dose limiting toxicities (DLTs) during DLT observation periodTime frame: Up to 21 days
- Part 1: Number of participants with treatment emergent adverse events (TEAEs) during DLT observation periodTime frame: Up to 21 days
- Part 3: Number of participants with treatment emergent adverse events (TEAEs) during DLT observation periodTime frame: Up to 21 days
- Part 1: Number of participants with dosage interruptions, dose reductions, and drug discontinuations for TEAEs during DLT observation periodTime frame: Up to 21 days
- Part 3: Number of participants with dosage interruptions, dose reductions, and drug discontinuations for TEAEs during DLT observation periodTime frame: Up to 21 days
- Part 2: Objective Response Rate (ORR)Time frame: Up to approximately 26 months
Locations
22 sites in 7 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
New York, New York
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Philadelphia, Pennsylvania
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Brussels, Belgium
GSK Investigational Site
Ghent, Belgium
GSK Investigational Site
Leuven, Belgium
GSK Investigational Site
Chiba, Japan
GSK Investigational Site
Shizuoka, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Tokyo, Japan
GSK Investigational Site
Amsterdam, Netherlands
GSK Investigational Site
Daegu, South Korea
GSK Investigational Site
Gyeonggi-do, South Korea
GSK Investigational Site
Seoul, South Korea
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Barcelona, Spain
GSK Investigational Site
Madrid, Spain
GSK Investigational Site
Málaga, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.